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Secretion systems translocate virulence factors of
many bacterial pathogens, enabling their survival
inside the host organism. Consequently, inhibition
strongly attenuates pathogenicity and can be con-
sidered a target for novel antimicrobial drugs. The
type IV secretion system (T4SS) of the intracellular
pathogen Brucella is a prerequisite for its virulence,
and in this work we targeted the interactions of
the essential assembly factor protein, VirB8, using
small-molecule inhibitors. High-throughput screen-
ing identified several potent and specific inhibitors,
and the target-binding site of these inhibitors was
identified by X-ray crystallography, in silico docking,
and analysis of the derivates of the inhibitor B8I-2.
VirB8 interaction inhibitors bind to a surface groove
opposite to the dimerization interface, and by varying
the binding-site residues, we were able to determine
which residues are required for inhibitor activity.
E115 and K182 were found to be especially impor-
tant, and changes at R114, Y229, and L151 also
reduced inhibitor efficiency.
INTRODUCTION
Bacterial virulence factors can be considered as suitable targets
for novel antimicrobial drugs that ‘‘disarm’’ bacterial pathogens
and thereby inhibit their survival within the host organism. These
so-called antivirulence drugs may provide novel therapeutic
options for the treatment of infections caused by multiresistant
bacteria or may be used to augment current therapies (Alksne
and Projan, 2000; Baron, 2010; Clatworthy et al., 2007). This
strategy gained significance most notably from the successful
targeting of different bacterial type III secretion systems (T3SS)
with small-molecule inhibitors isolated by in vivo functional
screening (Kauppi et al., 2003; Keyser et al., 2008; Muschiol
et al., 2006; Negrea et al., 2007; Tree et al., 2009). This in turn
led to the identification of broad-spectrum molecules that are
active against Salmonella, Shigella, and Chlamydia species,
but the nature of the screens implied that the cellular targetsChemistry & Biology 19, 1041–were not known a priori. Cellular targets of the most prominent
chemical class of T3SS inhibitors (salicylidene acylhydrazides)
were identified in a recent study (Wang et al., 2011); however,
this work did not permit an unambiguous correlation between
the targets and their effects upon secretion. Knowledge of the
target is a prerequisite for structure-activity relationship studies
and hit-to-lead development of drugs, and therefore it is critical
to identify the cellular targets and mechanism of this very prom-
ising class of inhibitors.
We have pursued an alternative strategy based on a target
protein with known structure. The target we selected was the
VirB8 protein, an essential assembly factor of bacterial T4SS
(Baron, 2006). T4SS are important virulence factors for many
Gram-negative pathogens, such asAgrobacterium,Brucella, Le-
gionella, and Helicobacter. Whereas T4SS form transenvelope
complexes (Alvarez-Martinez and Christie, 2009; Baron, 2005;
Fronzes et al., 2009), T3SS form needle-like structures that
are believed to originate from flagella (Cornelis, 2010; Moraes
et al., 2008) and thus have a completely different structure and
protein composition. Full-length VirB8 proteins contain a peri-
plasmic domain, a single transmembrane helix, and a short
5 kDa cytoplasmic domain. The X-ray crystal structures of the
periplasmic 18 kDa domains of VirB8 homologs from Agrobacte-
rium andBrucella have been solved to 2.2 and 2.4 A˚, respectively
(Bailey et al., 2006; Terradot et al., 2005). Both proteins exist as
homodimers, and amino acids at the dimer interface are critical
for protein function in both organisms (Paschos et al., 2006; Si-
vanesan and Baron, 2011). Based on knowledge that dimeriza-
tion is a prerequisite for functional VirB8, we conducted an in vivo
high-throughput screen using the bacterial two-hybrid (BTH)
system as the mode of analysis for dimerization of Brucella
VirB8, and isolated several specific inhibitors (Paschos et al.,
2011). Of interest, one of the most potent molecules, B8I-2,
belongs to the salicylidene acylhydrazide class of molecules,
which are also known to inhibit T3SS (Keyser et al., 2008). This
raises the possibility that despite the absence of obvious protein
sequence similarities, both of these secretion systems may be
inhibited by a similar mechanism.
Here we report the identification of the inhibitor-binding site on
VirB8 by X-ray crystallography, molecular docking, and site-
directed mutagenesis of critical amino acids at the binding site.
VirB8 interaction inhibitors bind to a surface groove opposite
to the dimerization site, and may inhibit a conformational change
that is required for protein function. We also conducted the first1048, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 1041
Figure 1. Dose Response andDetermination of the EC50 of B8I-1 and
B8I-2 VirB8 Interaction Inhibitors
E. coli strain BTH101 expressing fusions of VirB8 to the T18 and T25
domains of adenylate cyclase was cultivated in 96-well microtiter plates in
TGYEP medium, and the b-galactosidase activities reflecting the protein-
protein interaction were determined in the presence of inhibitors B8I-1 and
B8I-2 at concentrations from 0.01 to 100 mM. The EC50 values (effective
concentration leading to 50% reduction) are indicated, and the slope factors
of the curves are consistent with a single binding site on VirB8. The average
from 12 replicates is given and the standard deviation is shown. See also
Figure S1.
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at elucidating the critical features of inhibitor B8I-2, which will
enable the synthesis of more potent molecules in the future.
RESULTS
Characterization of VirB8 Inhibitors
VirB8 interaction inhibitors were originally identified in studies
that used the BTH assay as a high-throughput screening tool
(Paschos et al., 2011). The assay is based on a reporter system
that is based on the restoration of interactions between two split
domains (T18 and T25) of adenylate cyclase that are indepen-
dently fused to the N-terminal (cytoplasmic) domain of full-
length VirB8, such that the C-terminal (periplasmic) domain of
full-length VirB8 is localized in the periplasm of Escherichia
coli, simulating the natural environment of VirB8 in vivo (Kari-
mova et al., 2005). Among the 20 initial inhibitors of VirB8-
VirB8 interactions, eight of which were found to inhibit both
VirB8-VirB8 and VirB8-VirB10 (Paschos et al., 2011), we focused
on the five most potent molecules in a dose-response assay,
using 15 inhibitor concentrations in the range of 0.01–100 mM.
The most active molecules (B8I-1 to B8I-5) have EC50 values
(indicating 50% inhibition in an in vivo system) between 0.1
and 5 mM, and the slope factors of the curves suggest single-
hit binding sites on VirB8 for all molecules (Figure 1; see Fig-
ure S1 available online). This interpretation is reflected in the
change in the readout of the b-galactosidase activity, which
covered two log units in concentration, consistent with single-
site subunit binding for each inhibitor. Although the steepness
of the fitted curves or their slope factor alludes to cooperative
binding with values ranging between 1.7 and 2.4 (except for
B8I-5, which has a value of 1.1), the errors in the slope factors
make these values not statistically different from the expected
value of one for noncooperative behavior. Of interest, four of
the five most active molecules (B8I-2 to B8I-5) inhibited both
VirB8-VirB8 and VirB8-VirB10 interactions in the BTH assay,
which may indicate that their mechanism of action constitutes1042 Chemistry & Biology 19, 1041–1048, August 24, 2012 ª2012 Ela conformational change that affects both interactions (Paschos
et al., 2011).
Whereas the BTH assay provides a useful tool for in vivo
screening and quantitative analysis of inhibitor potency, the
results reflect the sum of different processes, including inhibitor
diffusion across the outer membrane and stability inside the cell.
Consequently, the efficacy of an inhibitor and its respective
target concentration within the cell are not well defined, which
in turn limits the quantitative analyses of inhibitor binding that
are required for a structure-activity relationship analysis. We
therefore developed a fluorescence resonance energy transfer
(FRET)-based in vitro assay to measure VirB8 dimerization. The
virB8 gene was mutagenized to change a surface residue,
Q139, to cysteine and selectively labeled using thiol-reactive
Alexa Fluor 488 C5 maleimide (donor) or Alexa Fluor 546 C5
maleimide (acceptor) fluorophores. Upon mixing of VirB8Q139C
labeled with either donor or acceptor fluorophores, the donor
was excited (488 nm) and the resulting emission spectrum
showed a reduction in the emission of the donor (520 nm) with
a concomitant increase in the acceptor emission (565 nm) indic-
ative of energy transfer via FRET. In dilution experiments, the KD
value of the VirB8Q139C-VirB8Q139C interaction was determined
to be 106 ± 2 mM, which is consistent with previous measure-
ments obtained by other approaches (Paschos et al., 2006,
2011).
Attempts to calculate an IC50 value (indicating 50% inhibition
in an in vitro system) using a unique concentration of VirB8
with increasing concentrations of VirB8 inhibitors (B8I-1, B8I-2,
and B8I-3) proved ineffective. Taking into account the experi-
mental error, one can only observe minor changes in FRET
by calculating the KD of VirB8-VirB8 in the presence of a given
inhibitor. Therefore, concentrated VirB8Q139C (R140 mM) was
incubated with the most biologically active inhibitor, B8I-2, in
a 1:1 stoichiometry of VirB8 to inhibitor, followed by dilution in
the presence of buffer supplemented with the inhibitor. Upon
dilution, a modest reduction in the FRET efficiency was ob-
served for every protein concentration and the calculated KD
for VirB8Q139C was 134 ± 3 mM. A similar experiment in which
a 10-fold excess of B8I-2 over protein was added yielded a KD
of 201 ± 3 mM, indicating a weakening of the dimerization of
VirB8, possibly due to a conformational change (Figure S2).
These KD values were found to be statistically different from
each other (p% 0.02) by means of a two-tailed t test.
X-Ray Crystallography and Docking Identify the
Inhibitor-Binding Site
To define the structural basis for the inhibition of VirB8 dimeriza-
tion, we used previously established crystallization conditions to
identify the inhibitor-binding site(s) by X-ray crystallography. The
purified periplasmic domain of Brucella VirB8 was cocrystallized
in the presence of VirB8 interaction inhibitors, the structures
were solved by molecular replacement using Phenix software
(Adams et al., 2002), and the model was built using COOT (Ems-
ley and Cowtan, 2004; Table 1). This approach identified the
inhibitor-binding site of molecule B8I-1 in a deep groove oppo-
site to the dimerization interface of VirB8. The binding site
comprises conserved surface-exposed residues where it forms
hydrogen bonds with residue K182 and close contacts with
Q144, the backbone carbonyl of R114, and hydrophobicsevier Ltd All rights reserved
Table 1. Data Collection and Refinement Statistics
VirB8/B8I-1 Complex Native VirB8
Data Collection
Resolution (A˚) 48-2.6 (2.67-2.60) 25.6-2.25 (2.29-2.25)
Wavelength 1.08 1.08
Unique reflections/
multiplicity
31,872/14.6
(2,335/14.8)
48,076/11.2
(2,644/4.5)
Completeness (%) 100 (100) 97.4 (73.5)
Average I/s(I) 24.2 (2.0) 37.29 (6.9)
Rsym
a 0.100 (1.22b) 0.044 (0.223)
Space group I4122 I4122
Unit cell parameters
a (A˚), b (A˚), c (A˚),
a = b = g = 90
199.05, 199.05,
103.45
199.05, 199.05,
103.42
Number of atoms
Protein 5329 5335
Water 481 961
Hetero 80 0
Rcryst (%)
c 20.81 18.97
Rfree (%)
d 23.47 22.34
Root mean square deviation
Bond length (A˚) 0.01 0.01
Bond Angle (o) 0.73 1.01
Average B-factor (A˚2) 55.2 37.8
Ramachandran Analysise (%)
Favored regions 98.3 98.0
Allowed regions 1.7 2
Luzatti error
in coordinates
0.25 0.24
All values in parentheses are given for the highest resolution shell.
aRsym = Shkl SijIi(hkl) - Ii(hkl)j/ Shkl SiIi(hkl) with i running over number of
independent observations of reflection hkl.
bRefer to Experimental Procedures for the Rsym value reported in the
outer resolution shell.
cRcryst = ShkljjIo(hkl)j - jIc(hkl)jj/ ShkljIo(hkl)j.
dRfree = ShklSTjj Io(hkl) - jIc(hkl)jj/ ShklSTjIo(hkl)j, where T is a test data set
randomly selected from the observed reflections prior to refinement.
The test data set was not used throughout refinement and contained
7.5% of total unique reflections.
eAnalyzed by Molprobity.
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Brucella VirB8 Interaction Inhibitorsinteractions between the butyl chain of B8I-1 and W198 (Fig-
ure 2A). VirB8I-1 binding displaced at least four structurally
bound water molecules from the binding pocket in each subunit
and did not induce detectable conformational changes with
respect to the structure of free VirB8.We did not observe binding
after cocrystallization or soaking with any of the other inhibitors,
indicating that they may not be able to compete for the dimer
interface or that the crystallization conditions precluded binding.
To determine the inhibitors’ binding site(s), we pursued an
alternative approach based on recently developed docking cal-
culations that have yielded predictions of binding sites that are
in very good agreement with crystallographically determined
sites. We performed in silico automated docking using Autodock
4 (Morris et al., 1998, 2008), and the results predict that the B8I-1
binding site corresponding to the lowest interaction energy isChemistry & Biology 19, 1041–virtually identical [root-mean-square deviation (rmsd) 0.87 A˚] to
that observed in the crystal structure (Figure 2B). This result vali-
dated the capability of the in silico docking algorithm to predict
inhibitor-binding sites in the VirB8 structure. Further application
using the same docking calculations predicted the binding site of
B8I-2, the molecule that inhibits intracellular growth of Brucella,
and the site coincides with the binding locus of B8I-1 (Figure 2C).
Subsequently, we docked the VirB8-VirB8–specific interaction
inhibitors B8I-3 toB8I-20 identically in order to identify a common
structure-function relationship between the mode and the site of
action of the inhibitor that was independent of the motif of the
small-molecule inhibitor. Intriguingly, the lowest interaction ener-
gies calculated for most other VirB8 inhibitory compounds coin-
cidedwith binding to the same surface binding site of the protein,
with the exception of the largest molecules, VirB8I-13 and VirB8-
17, which bound at a different VirB8 surface site that was distinct
from the dimer interface (Figure 2D). These results provide suffi-
cient high-resolution structural information for structure-activity
relationship studies to test the proposed mode of binding and
to create more potent molecules.
Analysis of B8I-2 Derivatives Supports the Proposed
Binding Mode
On the basis of the structural and docking analyses, we carried
out a first round of synthesis of small-molecule inhibitors derived
from B8I-2. This molecule was chosen because it inhibits the
pathogen Brucella in infection experiments, and thus has the
most interesting biological activity. We synthesized a small but
focused library of new compound analogs of 36 members to
probe the requirements for chemical functionality opposing the
central N-N hydrazide bond on both the left-hand side (LHS)
2-hydroxbenzamide moiety of the salicylidene ring, and the
right-hand side (RHS) furyl and 2-nitrophenyl moieties of the
B8I-2 basic structure (Figure 3). We tested the molecules using
the BTH assay, and whereas many of the more-severe changes
to the RHS or LHS of B8I-2 were not tolerated and yielded
no detectable inhibition of VirB8-VirB8 interaction, we observed
that subtle changes to the LHS and RHS portions of B8I-2
retained activity. A notable change concerned the position of
a single nitro group, from the ortho to the para position, which
led to a loss of activity (UM0125824; EC50 > 200 mM; Figure 3).
In contrast, a nitro group in the meta position on an analog in
which the furan ring is absent retained some detectable in vivo
activity, with an EC50 value of 51 mM (molecule UM0125850; Fig-
ure 3). This suggests that both an optimal N-N hydrazide dis-
tance and an optimal orientation of the nitro group are required
for sequestering in vivo. The LHS similarly appears to tolerate
only modest changes, such as the substitution of a hydroxyl
group from either the 2- (B8I-2) or 3- (UM0125823) position. In
contrast, the substitution of the phenolic moiety for a pyridine
(UM0125836) or 4-chlorobenzene (UM0125830) resulted in inac-
tive molecules (Table S1). The introduction of a second hydroxyl
group to the B8I-2 scaffold at the 5-position on the phenolic ring
(UM0125848; Figure 3) or the shifting of the single hydroxyl group
(UM0125823) yielded two molecules with activity similar to that
of B8I-2 in the BTH assay.
We next selected four inhibitors for in vitro and in silico
docking analyses: two active (UM0125823 and UM0125848),
one inactive (UM0125824), and one with low EC50 inhibition1048, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 1043
Figure 2. X-Ray Structure and Docking of
Inhibitors to VirB8
(A) The electron density derived from X-ray anal-
ysis encompassing B8I-1 was calculated from
a simulated annealing Fo-Fc omit map to 2.6 A˚
resolution and contoured at 3s. Side chains of
residues within a 5 A˚ radius of B8I-1 are depicted
by stick bonds. The small-molecule inhibitor
forms hydrogen bonds with amino acid K182. A
hydrogen-bond network among residues K182-
E115-Y229 is indicated that may stabilize the
structure of the surface groove of VirB8.
(B) Docked conformation of B8I-1 (orange) in
complex with VirB8 superposed onto the complex
observed in the crystal structure (blue; rmsd =
0.87 A˚ for all atoms of B8I-1) confirms the quality of
the docking prediction using AutoDock 4.
(C) Binding site of inhibitor B8I-2 (blue) in VirB8 as
predicted by AutoDock 4. B8I-1 (orange) shares
the same binding site as B8I-2. In addition to an
interaction with K182, common to both inhibitors,
the hydrogen-bond network consisting of residues
K182-E115-Y229 positions both E115 and K182
for interaction with B8I-2, enabling an additional
interaction by B8I-2 with R114.
(D) A cartoon representation of the VirB8monomer
(gray) shows the common binding site for 15 of 17 tested inhibitors as predicted by Autodock 4 (lower portion of image), which corresponds to the crystallographic
binding site for B8I-1 (orange). B8I-13 and B8I-17 are predicted to bind in a surface groove shown in the upper part of the image. Neither binding site is situated at
the VirB8 crystallographic dimer interface. Atoms for each inhibitor were colored using a rainbow gradient based on the relative intermolecular binding energy for
each inhibitor with VirB8 (lowest energy shown in blue, highest energy shown in red).
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Brucella VirB8 Interaction Inhibitors(UM0125850). Using the FRET-based VirB8 interaction assay,
we obtained KD values for VirB8
Q139C consistent with those
achieved for B8I-2 for UM0125823 (134 ± 3 mM) and
UM0125848 (141 ± 3 mM), whereas for UM0125824 and
UM0125850 the calculated KD values were lower and more
consistent with the DMSO-alone control (Figure 3). Of interest,
the results of in silico docking simulations largely predicted
the experimental outcomes, e.g., suggesting that molecule
UM0125824 has reduced binding and UM0125848 has slightly
increased affinity (Figure 3), which further supports the predictive
value of this approach.
All other molecules, including the T3SS inhibitors, were inac-
tive (see Table S1 for structures). These results are consistent
with the proposed binding mode from docking analysis of
B8I-2, and reveal important structural constraints that will
inform future rounds of synthesis aimed at creating improved
inhibitors.
Structure-Function Analysis of VirB8 Verifies the
Binding Site
To substantiate the proposed mode of binding, we changed six
residues at the inhibitor-binding site that are conserved and/or
are believed to stabilize binding via ionic, hydrophilic, or hydro-
phobic interactions (Y229, R114, E115, Q144, L151, and K182;
Figures 2A–2C). We expressed the VirB8 protein variants as
T18 or T25 adenylate cyclase domain fusions to the N terminus
of full-length VirB8, and analyzed them using the BTH assay.
We then tested the dimerization (Figure 4A) and stability in the
cell. This revealed that changes at E115, R114, and K182 appar-
ently reduced dimerization to 25%–55% that of the wild-type
(WT) level. All of the proteins were detectable with the T25/T181044 Chemistry & Biology 19, 1041–1048, August 24, 2012 ª2012 Eladenylate cyclase domain fusions to the N terminus of full-length
VirB8 (western blotting; not shown).
We next analyzed whether the variants with changes made at
the binding site [E115(A/Q), K182(A/E), R114(M/Q), L151(Y/R),
Y229(F), and Q144(R/L)] are susceptible to inhibition. To that
end, we calculated the reduction in dimerization as compared
with that in the absence of the inhibitor. The inhibitor efficiency
(IE) is calculated as [relative inhibition of the variant / relative inhi-
bition of the WT] 3 100. This analysis revealed a significant
degree of resistance of the E115(A/Q) and K182(A/E) variants
to both inhibitors (IE 17%–56%). In contrast, the effects were
more modest for both R114Q and Y229(F), and the IE was
reduced more for B8I-1 than for B8I-2 (Figure 4B). The L151(Y/
R) change was also found to reduce IE modestly to 60%,
whereas changes at Q144(R/L) had no effect. The result that
changes at the binding site led to various degrees of resistance
to inhibition confirms the predictions from X-ray analysis, in silico
docking, and the B8I-2 binding mode.
DISCUSSION
The work presented here constitutes the first (to our knowledge)
report of a T4SS inhibitor with an identified target and validated
binding site, and lays the groundwork for the design of antiviru-
lence drugs aimed at the inhibition of T4SS. Building on our
previous attempts to isolate type IV secretion inhibitors using
VirB8 as a target, we have now identified the binding site of these
molecules. VirB8 interaction inhibitors bind to a deep surface
groove of the protein that is on the face of the VirB8 monomer
opposite to that of the predicted dimerization site. The binding
site revealed here by X-ray crystallography and docking wassevier Ltd All rights reserved
Figure 3. Analysis of Selected B8I-2 Deriva-
tives Using In Vivo BTH and In Vitro FRET
Assays and In Silico Docking
Structures of B8I-2 and derivatives that do
(UM0125823 and UM0125848) or do not
(UM0125824) preserve activity or have strongly
reduced activity (UM0125850). The table indicates
the respective EC50 values obtained using the
BTH assay in vivo, docking energies determined
in silico using Autodock software, and a FRET-
based dilution assay to determine the impact of
B8I-2 derivatives on the KD of VirB8. KD values for
the DMSO control versus B8I-2, UM0125823, and
UM0125848 were found to be statistically different
from each other (p% 0.02) using a two-tailed t test.
See also Table S1.
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binding at the dimer interface. However, the in silico, in vitro,
and in vivo data presented here confirm the identity and biolog-
ical significance of this site.
VirB8 interaction inhibitors bind in a groove that offers a deep
hydrophobic pocket formed by Q144, L151, Y155, K182, R114,
and E115, which can accommodate both the charged and
hydrophobic functional groups of the small molecules. Changes
tomost of these amino acids, using site-directed mutagenesis of
the virB8 gene, affected IE to various degrees, with two of the
variants E115A and K182E demonstrating high resistance to
inhibitors B8I-1 and B8I-2. Considering that B8I-1 and B8I-2
are structurally quite different, the very similar effects of changes
at the binding site on both molecules suggest that they influence
VirB8 function via a similar mechanism. The inhibitors may target
the hydrogen-bond network that is predicted to exist among
residues E115, K182, and Y229, which may in turn lead to a
conformational change of the protein that is required for its inter-
actions. This notion is supported by additional BTH assays sug-
gesting that heterodimers of VirB8Wt-VirB8variant (where variant
indicates E115Q/A, K182E/A, or R114M/Q) respond almost iden-
tically to variant homodimers (M.A.S. and C.B., unpublished
data). This may imply that only a single monomer is required
to bind a molecule of inhibitor in order to reveal an effect on
dimerization. The fact that inhibitors B8I-2 to B8I-5 inhibit the
VirB8-VirB8 and VirB8-VirB10 interactions is consistent with
this proposal (Paschos et al., 2011).
It is conceivable that inhibitor binding inducesa conformational
change that may be transduced via the a helix that begins withChemistry & Biology 19, 1041–1048, August 24, 2012 ªthe critical residue E115 at the inhibitor-
binding site and terminates with residue
M102 at the dimerization site (Figure 4C).
Changes of certain residues along this
a helix (D103, Y110, and Y206) also
reduce dimerization in the BTH assay
(M.A.S. and C.B., unpublished data),
which is consistent with the idea that
binding of inhibitors in the surface
groove may trigger subtle conformational
changes that reduce dimerization. This
change could be further transmittedthrough the transmembrane domain that is located only a short
distance away from this helix, but for which no structure is avail-
able. Indeed, the weak effect of B8I-2 in the FRET-based interac-
tion assay indicating a modest conformational change is consis-
tent with this hypothesis. Our results suggest that the analysis of
the periplasmic domain alone in vitro does not permit us to
monitor the effect of the inhibitor on the full-length protein. It
would therefore be interesting to test this hypothesis using puri-
fied full-length VirB8 and its variants, e.g., after incorporation into
nanodiscs (Bayburt and Sligar, 2010; Dalal and Duong, 2010).
Recent work by Bourg et al. (2009) testing the interactions of
chimeras of B. suis VirB8 with the E. coli VirB8 homolog TraJ
showed an important contribution of the TraJ transmembrane
region. Similarly, Andrieux et al. (2011) demonstrated that vari-
ants with changes of two glycine residues within the transmem-
brane helix (G49 andG59) to aromatic residues strengthened the
interaction and were unable to restore virulence to Brucella.
Alternatively, the surface groove may close or have greater
dynamism upon and/or during dimerization within the cell, and
bound inhibitors may block or perturb this flexibility. The avail-
able crystallographic data of VirB8 and VirB8-B8I1 indicate no
gross structural changes. The C-a rmsd between the two struc-
tures is 0.27 A˚ and they possess similar conformational states of
side chains. However, the structural work was carried out with
the periplasmic domain of the protein, and the observed struc-
tures may not fully reflect the complete conformational state
of the membrane-bound protein. Additionally, X-ray crystallog-
raphy is not the optimal approach for studying subtle changes
in protein dynamics, and we have initiated analysis by2012 Elsevier Ltd All rights reserved 1045
Figure 4. Structure-Function Analysis of the
Inhibitor-Binding Site
Six residues at the inhibitor-binding site were
changed by site-directed mutagenesis to assess
the contributions of their charge and hydropho-
bicity to inhibitor activity.
(A) The variants E115A/Q, K182E/A, R114M/Q,
Y229F, Q144L/R, and L151Y/R were expressed
and their dimerization was tested in the BTH
assay.
(B) Test of the ability of inhibitors B8I-1 and B8I-2
(20 mM) to inhibit dimerization [the level of dimer-
ization observed in (A) was set to 100%]. The IE is
calculated as [relative inhibition of the variant/
relative inhibition of the WT] 3 100. Low IE values
indicate that the inhibitor does not inhibit dimer-
ization, and high IE values indicate that it is
effective. Error bars in (A) and (B) indicate the SEM
conducted from a minimum of triplicate replicates
(nR 3) for the binding-site variants.
(C) Model of the VirB8 dimer with critical residues
required for inhibition by B8I-1/2 shown in red
(E115 and K182) and less important residues
shown in yellow (R114, Y229, and L151). The
dimerization site with its critical residue M102 is
indicated in green. The a helix linking the inhibitor-
binding site and the dimerization site is labeled
in blue.
(D) Interactions of important inhibitor-binding
site residues with B8I-1 (cocrystal structures) and
B8I-2 (model derived from docking).
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address this question. Nevertheless, E115, K182, and R114
represent highly conserved residues among VirB8 proteins,
and the data presented here confirm that they form part of the
binding site. Future work will clarify their mechanistic contribu-
tion to the dimerization of the WT protein.
The isolation of small-molecule inhibitors enabled the de-
velopment of a complementary approach to mutagenesis for
studying the binding site by synthesizing derivates. In this
work, we conducted the first round of a structure-activity rela-
tionship analysis program aimed at elucidating the constraints
for B8I-2 binding. Of the 36 molecules examined, those that
carried more substantial changes were inactive in the BTH
assay, showing that the binding site is rather specific for B8I-2,
which also applies to the seven type III secretion inhibitors that
are also salicylidene acylhydrazides (Keyser et al., 2008). Indeed,
the fact that they are inactive in the VirB8 interaction assay
suggests that the chemical similarity may be coincidental.
Nevertheless, it would be interesting to assess whether VirB8
interaction inhibitors bind to and inhibit interactions of T3SS
components, which could indicate similarities in the mechanism
of inhibition. More subtle changes of B8I-2 showed that both the
presence and addition of a hydroxyl group, located on the 2-hy-
droxbenzamide moiety of the salicylidene ring, on the LHS of the
molecule is required as well as the positioning of the nitro group
at the RHS. These results reveal important constraints for future
work aimed at synthesizing more potent molecules, and are
consistent with the binding of B8I-2 and B8I-1 to E115, K182,
and R114 that was predicted by docking. Docking largely pre-
dicted the biological activity of novel B8I-2 derivates, and in1046 Chemistry & Biology 19, 1041–1048, August 24, 2012 ª2012 Elthe future we will use this approach together with structure
biological and biochemical assays to develop improved inhibi-
tors (in particular, with the goal of enhancing their solubility)
that can also be applied to study the mechanism of VirB8
interactions.
SIGNIFICANCE
Wide-scale bacterial resistance to antimicrobial drugs is
currently a global problem, and classical approaches target-
ing metabolic pathways have culminated in a strong selec-
tion pressure that has contributed toward increasingly mul-
tiresistant strains of bacteria. An alternative strategy would
be to develop antivirulence drugs that target bacterial viru-
lence factors so that once the bacterium is ‘‘disarmed,’’
the host immune system can eliminate the pathogen. We
have developed potent and specific small-molecule inhibi-
tors toward the T4SS from the intracellular pathogen
Brucella targeting an essential assembly protein, VirB8. By
employing a multidisciplinary approach, we were able to
identify the binding site of the inhibitor B8I-1. We then
used in silico prediction to validate this site, together with
the binding mode of the most potent inhibitor of the intra-
cellular replication of Brucella in a macrophage infection
model, B8I-2, by employing a combination of in vivo and in-
vitro approaches. We conducted an initial round of struc-
ture-activity relationships by synthesizing 36 novel inhibitors
based on the B8I-2 scaffold, and the results were again
consistent with those predicted in silico. In summary, we
report, to our knowledge, the first validated structure ofsevier Ltd All rights reserved
Chemistry & Biology
Brucella VirB8 Interaction Inhibitorsa component of a secretion system bound to a small-mole-
cule inhibitor of bacterial virulence. Additionally, the chemi-
cal biology approach employed here enabled us to gain very
interesting insights into the mechanism of the VirB8 protein
during assembly of the T4SS. This work provides an innova-
tive approach that can serve as a model for investigating
microbial virulence mechanisms.EXPERIMENTAL PROCEDURES
Description of strains and plasmids used as well as details of oligonucleotide
sequences can be found in Tables S2 and S3, respectively.BTH Assay, Dose-Response Determination of EC50 Values, and IE
Calculations
BTH assays were carried out as described previously (Paschos et al., 2011)
and conducted in a minimum of triplicate replicates for the binding-site
variants and a maximum of 12 replicates for the dose-response curves of
B8I-1/2/3/4/5. EC50 determinations were performed as above with strain
BTH101 freshly transformed with pUT18CB8 and pKT25B8 (or pUT18C
and pKT25B8 control), and the compounds were added at concentrations
of 0.01–250 mM. Data analysis was conducted with the use of GraFit 6.0.
The percentage IE normalized to WT VirB8-VirB8 interaction was calculated
using the equation E = (DMvariant/DMWT) 3 100, where M is the calcu-
lated Miller unit value for the variant and WT VirB8 proteins, respectively.
A lower E value for a variant indicated a reduced efficiency of the given
inhibitor.Identification and Refinement of B8I-1 Binding
The crystal structure of VirB8 in complex with B8I-1 was first refined without
regard to inhibitor binding. The position of B8I-1 in complex with VirB8 corre-
sponding to the lowest-energy conformation predicted by the docking calcu-
lations was then superimposed on the equivalent positions in each VirB8
subunit in the crystallographic asymmetric unit cell. Inspection of the electron
density map showed an unambiguous fit to the electron density by B8I-1 in
subunits C and D, and these B8I-1 positions were further refined. A B-factor
comparison with residues surrounding B8I-1 suggested partial occupancy
by B8I-1 in the VirB8 subunits. B8I-1 was then built into the remaining subunits
based on its predicted position, and B8I-1 molecules were refined in alternate
conformation with a group of four to six water molecules occupying the same
site in the equivalent native VirB8 subunits. The B-factors for both B8I-1 and
water molecules were set to the mean B-factor of atoms within 10 A˚ of
B8I-1 in each subunit, and their occupancies were included as variables in
further refinement. Water molecules with refined occupancies < 0.2 were
then deleted, and this was followed by a final round of refinement that yielded
occupancies for B8I-1 of 0.45, 0.35, 0.65, 0.8, and 0.25 in subunits A, B, C, D,
and E, respectively.Docking Simulation
AutodockTools software (Morris et al., 1998, 2008) was used to add polar
hydrogen to the VirB8 subunit A structure of PDB code 2bhm (Terradot
et al., 2005), and Gaisteger charges were then calculated for each atom.
Affinity grids of 1203 1203 120 A˚ with 0.3 A˚ spacing positioned on the center
of mass of the subunit were calculated using autogrid4 for each atom type
found in the compounds. Chemical structures for each ligand were retrieved
from the hit2lead.com website and converted to PDB format using openbabel
and phenix.elbow software. The script prepare_ligand4.py (ADT utilities) was
used to add hydrogen atoms, Gaisteger charges, and atom types to each
file. The Autodock 4.0 docking calculation used the Lamarckian genetic algo-
rithm with a population size of 150 individuals; 25 million energy evaluations;
a maximum of 27,000 generations, with one top individual to survive to the
next generation; a mutation rate of 0.02; and a crossover rate of 0.8. The local
search probability was set to 0.06 with 300 iterations. Each docking simulation
was run 100 times, and the resulting conformations were clustered using a 2 A˚
rmsd threshold.Chemistry & Biology 19, 1041–Supplemental Experimental Procedures
Expression, protein purification, crystallization, structure determination, FRET
assay conditions, and synthesis of B8I-2 derivative are reported in the Supple-
mental Experimental Procedures.
ACCESSION NUMBERS
The atomic coordinates and structure factors for free VirB8 and in complex
with B8-1 have been deposited with the Protein Data Bank (4akz and 4aky,
respectively).
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures, three tables, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2012.07.007.
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